January 8, Adagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic.
April 24, Adagene and ADC Therapeutics Announce SAFEbodyTM License Agreement.
March 4, Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation.
January 7, Adagene Announces Collaboration for Discovery of Novel CAR-T with the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH).
October 31, Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106.
July 9, US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lymphoma Ph1 Trial.
March 26, Adagene announced a $50 million Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.
March 9, Adagene and WuXi Biologics Announce Strategic Development and Manufacturing Partnership
January 28, Adagene announced a $28 million Series B financing led by GP Healthcare Capital. Joining this round were new investor New World TMT and current investors Eight Roads Ventures China (formerly Fidelity Growth Partners Asia), F-Prime Capital (formerly Fidelity Biosciences) and WuXi Corporate Venture Fund.
December 8, Adagene announced the closing of an $8 million Series A financing with backing from Fidelity Biosciences, a leading investor in innovative world-class healthcare technologies; Fidelity Asia Growth, a leading investor in global innovative companies in Asia; and WuXi Venture Fund, the investment arm of WuXi PharmaTech, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States.
February 28, Adagene established in Suzhou, China.
©Copyright-Adagene 2019